Enliven Therapeutics ELVN Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$98.78M-4.2% | -$103.69M-16.5% | -$97.21M-14.1% | -$100.22M-21.0% | -$94.83M-19.1% | ||
| $203K-34.9% | $263K-17.0% | $297K-5.7% | $315K+0.6% | $312K+1.0% | ||
| $34.62M+54.1% | $34.02M+68.6% | $27.05M+51.2% | $25.04M+55.4% | $22.46M+48.1% | ||
| —— | -$106K-864% | -$82.25K— | -$58.5K— | -$34.75K— | ||
| $78K— | $817K— | $312K— | —— | —— | ||
| —— | —— | —— | —— | $322K-95.7% | ||
| -$365K-13.7% | -$337K-0.6% | -$331K-0.6% | -$325K+31.4% | -$321K+18.1% | ||
| -$65.47M+11.5% | -$70.3M+3.9% | -$71.67M-4.7% | -$70.58M+2.2% | -$73.96M-15.9% | ||
| —— | —— | —— | $181K+248% | $44K-68.1% | ||
| —— | $213K— | $159.75K— | $106.5K— | $53.25K— | ||
| -$145.12M— | -$186.22M— | —— | —— | —— | ||
| $12.11M+5,077% | $2.3M— | $1.77M— | $1.56M— | $234K— | ||
| $229.05M+431% | $219.24M+64.6% | $258.58M+177% | $259.7M— | $43.13M— | ||
| —— | —— | —— | —— | -$47.51M— | ||
| —— | —— | -$694K-130% | -$1.72M-134% | -$1.04M-120% | ||
| $203K-34.9% | $263K-17.0% | $297K-5.7% | $315K+0.6% | $312K+1.0% | ||
| —— | -$106K-864% | -$82.25K— | -$58.5K— | -$34.75K— | ||
| —— | —— | —— | —— | $322K-95.7% | ||
| -$365K-13.7% | -$337K-0.6% | -$331K-0.6% | -$325K+31.4% | -$321K+18.1% | ||
| —— | —— | —— | —— | —— | ||
| $361K+10.7% | $353K+10.3% | $342K+7.9% | $333K-28.4% | $326K-15.3% | ||
| —— | $213K— | $159.75K— | $106.5K— | $53.25K— | ||
| —— | $0-100% | $9.8M-66.7% | $19.59M0.0% | $29.39M+200% | ||
| -$365K-13.7% | -$337K-0.6% | -$331K-0.6% | -$325K+31.4% | -$321K+18.1% | ||
| —— | —— | —— | —— | $736K— | ||
| —— | —— | -$5K-120% | -$118K-161% | -$50K-140% | ||
| -$65.6M+11.3% | -$70.46M+3.8% | -$71.82M-4.8% | -$70.76M+2.0% | -$74M-15.8% | ||
| -$65.6M+11.3% | -$70.46M+3.8% | -$71.82M-4.8% | -$70.76M+2.0% | -$74M-15.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Enliven Therapeutics generate?
- Enliven Therapeutics (ELVN) generated -$65.5M in operating cash flow over the trailing twelve months.
- What is Enliven Therapeutics's free cash flow?
- After $159.0K of capital expenditures, Enliven Therapeutics's free cash flow was -$65.6M over the trailing twelve months, up 11.3% year over year.
- Where does Enliven Therapeutics's cash flow data come from?
- Every line is extracted from Enliven Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.